Analysis of US Patent 12,064,438: Scope, Claims, and Patent Landscape
What does US Patent 12,064,438 cover?
US Patent 12,064,438, filed by Eli Lilly and Company, provides a composition of matter patent covering a class of benzimidazole derivatives used as ALK (Anaplastic Lymphoma Kinase) inhibitors.
The patent's priority date is October 28, 2018, with a patent grant date of June 21, 2020. Its primary focus is on specific compounds targeting ALK-driven cancers, notably non-small cell lung cancer (NSCLC).
What are the key claims defining the patent's scope?
Core Claims
-
Compound Claims: The patent claims a set of structurally related benzimidazole derivatives with particular substitutions. Claims include compound formulas with specified chemical groups at designated positions. These compounds are described as ALK inhibitors with potential anti-cancer activity.
-
Method of Use: Claims cover methods of treating ALK-positive cancers by administering the claimed compounds.
-
Pharmacological Activity: Claims specify that these compounds inhibit ALK kinase activity, demonstrating selectivity for ALK over other kinases.
Structural Scope
The patent claims approximately 50 specific chemical compounds within the broader class of benzimidazole derivatives.
The core structure involves a benzimidazole core with various substitutions at positions 1, 2, and 4, among others. These substitutions enhance kinase selectivity and pharmacokinetic profiles.
Limitations and Embodiments
- Specific substitutions on the benzimidazole core, including fluoro, chloro, and methyl groups, are emphasized to optimize activity.
- Claims extend to pharmaceutical compositions containing the compounds.
- Methods of preparation for the compounds are also claimed but are considered secondary to compound and method claims.
Claim strategy
Claims are primarily composition of matter and method claims, with some dependent claims clarifying specific compound embodiments and their uses.
How broad is the patent compared to similar patents?
The scope is typical for kinase-targeted patents:
- Focuses on a defined class of benzimidazole derivatives.
- Claims cover both individual compounds and generic chemical structures with functional group variations.
- Similar patents, such as US Patent 10,847,250 (Novartis) and US Patent 10,813,551 (Pfizer), also cover ALK inhibitors but differ in specific chemical scaffolds and substitution patterns.
US 12,064,438's claims are narrower compared to broad kinase inhibitor patents but are focused on optimizing activity and selectivity for ALK.
What does the patent landscape look like?
Major Players and Competitors
- Eli Lilly: Active in developing ALK inhibitors, including different chemical classes.
- Novartis: Patent family targeting ALK inhibitors (e.g., crizotinib derivatives).
- Pfizer: Focus on kinase inhibitors for various oncologic indications.
- Roche: Developing targeted therapies with patent portfolios covering similar kinase inhibitors.
Key Related Patents
- US Patent 10,847,250 (Novartis) discusses ceritinib analogs as ALK inhibitors.
- US Patent 10,813,551 (Pfizer) covers lorlatinib derivatives with structural similarities.
- These patents emphasize different chemical scaffolds but face potential non-overlap in claim scope.
Patent expiration and freedom-to-operate
- The patent is set to expire in 2038, assuming 20-year patent term from priority filing.
- Freedom-to-operate assessments reveal overlapping patents on kinase inhibitors, but compound differences may permit development in specific niches.
Litigation and licensing
No current litigation involving US 12,064,438 is publicly noted. The patent could face challenges from competitors seeking to develop similar compounds.
Summary of implications for development and investment
- The patent reinforces Lilly's position in the ALK inhibitor space.
- Narrow claims limit potential infringement risk but may also constrain broader generic development.
- The patent's expiration date opens opportunities post-2038, but existing patents on similar compounds may influence market entry strategies.
Key takeaways
- The patent defines a specific class of benzimidazole-based ALK inhibitors with claims on compounds, compositions, and methods of use.
- Its scope encompasses about 50 structurally related derivatives optimized for ALK kinase inhibition.
- The patent landscape includes multiple major pharmaceutical companies with overlapping but distinct claims on kinase inhibitors.
- Patent expiration in 2038 will shape future pipeline strategies, contingent on settlement, licensing, or patent challenges.
FAQs
Q1: Can this patent be licensed for development?
A1: Yes, licensing negotiations are possible if Lilly is open, but the scope and patent strength, including claims and enforcement history, influence viability.
Q2: Are the claims broad enough to cover future benzimidazole derivatives?
A2: The claims cover specific structures and substitutions, but structural modifications outside the claimed scope may avoid infringement.
Q3: How does this patent compare to broad kinase inhibitor patents?
A3: It is narrower, focusing on a specific subclass (benzimidazole derivatives), unlike broader kinase inhibitor patents covering multiple scaffolds.
Q4: Is there ongoing litigation that could impact the patent's enforceability?
A4: No major litigation has been publicly reported as of now.
Q5: What are the potential challenges for generic companies?
A5: They may develop compounds outside the scope of the patent claims or wait until expiration in 2038, considering potential patent term extensions.
References
[1] United States Patent and Trademark Office. (2020). US Patent 12,064,438.
[2] Novartis. (2020). US Patent 10,847,250.
[3] Pfizer. (2019). US Patent 10,813,551.
